Anixa Biosciences Inc (Form: 10-Q, Received: 06/10/2021 16:31:43)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2021

Commission file number 001-37492

ANIXA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		11-2622630
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

3150 Almaden Expressway, Suite 250

San Jose, CA

95118

(Address of principal executive offices)

(Zip Code)

(408) 708-9808

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of exchange on which registered
Common Stock, par value $.01 per share		ANIX		NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer [ ]			Accelerated filer [ ]
	Non-accelerated filer [X]		Smaller reporting company [X]	Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

On June 10, 2021 the registrant had outstanding 29,949,905 shares of Common Stock, par value $.01 per share, which is the registrant’s only class of common stock.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.	1

Condensed Consolidated Balance Sheets as of April 30, 2021 (Unaudited) and October 31, 2020	1

Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended April 30, 2021 and 2020	2

Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) for the three months ended April 30, 2021 and 2020	3

Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) for the six months ended April 30, 2021 and 2020	4

Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended April 30, 2021 and 2020	5

Notes to Condensed Consolidated Financial Statements (Unaudited)	6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	21

Item 3. Quantitative and Qualitative Disclosures About Market Risk.	26

Item 4. Controls and Procedures.	26

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.	27

Item 1A. Risk Factors.	27

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.	27

Item 3. Defaults Upon Senior Securities.	27

Item 4. Mine Safety Disclosures.	27

Item 5. Other Information.	27

Item 6. Exhibits.	27

SIGNATURES	28

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	April 30, 2021			October 31, 2020
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	27,703,435		$	6,417,061
Short-term investments		10,399,300			2,640,000
Prepaid expenses and other current assets		369,213			311,563
Total current assets		38,471,948			9,368,624

Operating lease right-of-use asset		25,574			54,340
Other assets		-			30,000
Total assets	$	38,497,522		$	9,452,964

LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	438,013		$	232,368
Accrued expenses		978,894			901,025
Operating lease liability		25,964			55,198
Total current liabilities		1,442,871			1,188,591

Commitments and contingencies (Note 10)

Equity:
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding		-			-
Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding		-			-
Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,449,905 and 24,248,695 shares issued and outstanding, respectively		314,499			242,486
Additional paid-in capital		233,742,019			200,354,488
Accumulated deficit		(196,442,760	)		(191,835,618	)
Total shareholders’ equity		37,613,758			8,761,356
Noncontrolling interest (Note 1)		(559,107	)		(496,983	)
Total equity		37,054,651			8,264,373

Total liabilities and equity	$	38,497,522		$	9,452,964

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the Three Months Ended						For the Six Months Ended
	April 30,						April 30,
	2021			2020			2021			2020

Revenue	$	-		$	-		$	512,500		$	-

Operating costs and expenses:
Inventor royalties, contingent legal fees, litigation and licensing expenses		-			-			385,002			-
Research and development expenses (including non-cash share-based compensation expenses of $447,176, $458,132, $737,382 and $855,655, respectively)		1,022,176			1,228,790			1,849,827			2,719,378
General and administrative expenses (including non-cash share-based compensation expenses of $604,096, $651,954, $1,299,989 and $1,275,765, respectively)		1,415,106			1,441,347			2,948,084			2,580,628
Total operating costs and expenses		2,437,282			2,670,137			5,182,913			5,300,006

Loss from operations		(2,437,282	)		(2,670,137	)		(4,670,413	)		(5,300,006	)

Interest income		393			12,147			1,147			25,441

Net loss		(2,436,889	)		(2,657,990	)		(4,669,266	)		(5,274,565	)

Less: Net loss attributable to noncontrolling interest		(38,038	)		(17,897	)		(62,124	)		(41,929	)

Net loss attributable to common shareholders	$	(2,398,851	)	$	(2,640,093	)	$	(4,607,142	)	$	(5,232,636	)

Net loss per common share attributable to common shareholders:
Basic and diluted	$	(0.08	)	$	(0.12	)	$	(0.17	)	$	(0.25	)

Weighted average common shares outstanding:
Basic and diluted		28,669,475			21,155,505			26,887,974			20,927,212

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)

FOR THE THREE MONTHS ENDED APRIL 30, 2021

					Additional					Total			Non-
	Common Stock				Paid-in		Accumulated			Shareholders’			controlling			Total
	Shares		Par Value		Capital		Deficit			Equity			Interest			Equity

Balance, January 31, 2021		26,179,122	$	261,791	$	207,382,102	$	(194,043,909	)	$	13,599,984		$	(521,069	)	$	13,078,915
Stock option compensation to employees and directors		-		-		880,776		-			880,776			-			880,776
Stock options and warrants issued to consultants		-		-		170,496		-			170,496			-			170,496
Common stock issued upon exercise of stock options		77,571		776		188,604		-			189,380			-			189,380
Common stock issued pursuant to employee stock purchase plan		1,634		16		2,984		-			3,000			-			3,000
Common stock issued in a public offering, net of offering expenses of $2,208,150		4,285,715		42,858		20,248,996		-			20,291,854			-			20,291,854
Common stock issued in at-the-market offering, net of offering expenses of $156,265		905,863		9,058		4,868,061		-			4,877,119			-			4,877,119
Net loss		-		-		-		(2,398,851	)		(2,398,851	)		(38,038	)		(2,436,889	)

Balance, April 30, 2021		31,449,905	$	314,499	$	233,742,019	$	(196,442,760	)	$	37,613,758		$	(559,107	)	$	37,054,651

FOR THE THREE MONTHS ENDED APRIL 30, 2020

					Additional					Total			Non-
	Common Stock				Paid-in		Accumulated			Shareholders’			controlling			Total
	Shares		Par Value		Capital		Deficit			Equity			Interest			Equity

Balance, January 31, 2020		20,841,309	$	208,413	$	189,646,000	$	(184,409,806	)	$	5,444,607		$	(447,007	)	$	4,997,600
Stock option compensation to employees and directors		-		-		1,055,331		-			1,055,331			-			1,055,331
Stock options and warrants issued to consultants		-		-		54,755		-			54,755			-			54,755
Common stock issued upon exercise of stock options		25,000		250		75,000		-			75,250			-			75,250
Common stock issued pursuant to employee stock purchase plan		9,618		96		15,356		-			15,452			-			15,452
Common stock issued in at-the-market offering, net of offering expenses of $57,324		603,408		6,034		1,275,818		-			1,281,852			-			1,281,852
Net loss		-		-		-		(2,640,093	)		(2,640,093	)		(17,897	)		(2,657,990	)

Balance, April 30, 2020		21,479,335	$	214,793	$	192,122,260	$	(187,049,899	)	$	5,287,154		$	(464,904	)	$	4,822,250

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)

FOR THE SIX MONTHS ENDED APRIL 30, 2021

					Additional					Total			Non-
	Common Stock				Paid-in		Accumulated			Shareholders’			controlling			Total
	Shares		Par Value		Capital		Deficit			Equity			Interest			Equity

Balance, October 31, 2020		24,248,695	$	242,486	$	200,354,488	$	(191,835,618	)	$	8,761,356		$	(496,983	)	$	8,264,373
Stock option compensation to employees and directors		-		-		1,755,638		-			1,755,638			-			1,755,638
Stock options and warrants issued to consultants		-		-		281,733		-			281,733			-			281,733
Common stock issued upon exercise of stock options		107,451		1,075		292,529		-			293,604			-			293,604
Common stock issued pursuant to employee stock purchase plan		1,634		16		2,984		-			3,000			-			3,000
Common stock issued in a public offering, net of offering expenses of $2,208,150		4,285,715		42,858		20,248,996		-			20,291,854			-			20,291,854
Common stock issued in at-the-market offering, net of offering expenses of $340,775		2,806,410		28,064		10,805,651		-			10,833,715			-			10,833,715
Net loss		-		-		-		(4,607,142	)		(4,607,142	)		(62,124	)		(4,669,266	)

Balance, April 30, 2021		31,449,905	$	314,499	$	233,742,019	$	(196,442,760	)	$	37,613,758		$	(559,107	)	$	37,054,651

FOR THE SIX MONTHS ENDED APRIL 30, 2020

					Additional					Total			Non-
	Common Stock				Paid-in		Accumulated			Shareholders’			controlling			Total
	Shares		Par Value		Capital		Deficit			Equity			Interest			Equity

Balance, October 31, 2019		20,331,754	$	203,317	$	186,849,299	$	(181,817,263	)	$	5,235,353		$	(422,975	)	$	4,812,378
Stock option compensation to employees and directors		-		-		2,019,211		-			2,019,211			-			2,019,211
Stock options and warrants issued to consultants		-		-		112,209		-			112,209			-			112,209
Common stock issued upon exercise of stock options		43,900		439		103,291		-			103,730			-			103,730
Common stock issued pursuant to employee stock purchase plan		9,618		96		15,356		-			15,452			-			15,452
Common stock issued in at-the-market offering, net of offering expenses of $158,296		1,094,063		10,941		3,022,894		-			3,033,835			-			3,033,835
Net loss		-		-		-		(5,232,636	)		(5,232,636	)		(41,929	)		(5,274,565	)

Balance, April 30, 2020		21,479,335	$	214,793	$	192,122,260	$	(187,049,899	)	$	5,287,154		$	(464,904	)	$	4,822,250

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the six months ended April 30,
	2021			2020
Cash flows from operating activities:
Reconciliation of net loss to net cash used in operating activities:
Net loss	$	(4,669,266	)	$	(5,274,565	)
Stock option compensation to employees and directors		1,755,638			2,019,211
Stock options and warrants issued to consultants		281,733			112,209
Depreciation of property and equipment		-			29,418
Gain on sale of equipment		(5,447	)		-
Amortization of operating lease right-of-use asset		28,766			25,055
Change in operating assets and liabilities:
Prepaid expenses and other current assets		(57,650	)		102,909
Accounts payable		205,645			(415,039	)
Accrued expenses		77,869			(45,343	)
Operating lease liability		(29,234	)		(24,509	)
Net cash used in operating activities		(2,411,946	)		(3,470,654	)

Cash flows from investing activities:
Disbursements to acquire short-term investments		(10,399,300	)		(2,620,000	)
Proceeds from maturities of short-term investments		2,640,000			2,350,000
Purchase of property and equipment		-			(15,791	)
Proceeds from sale of equipment		35,447			-
Net cash used in investing activities		(7,723,853	)		(285,791	)

Cash flows from financing activities:
Gross proceeds from sale of common stock in a public offering		22,500,004			-
Expenses of the public offering		(2,208,150	)		-
Gross proceeds from sale of common stock in an at-the-market offering		11,174,490			3,192,131
Expenses of the at-the-market offering		(340,775	)		(158,296	)
Proceeds from sale of common stock pursuant to employee stock purchase plan		3,000			15,452
Proceeds from exercise of stock options		293,604			103,730
Net cash provided by financing activities		31,422,173			3,153,017

Net increase (decrease)in cash and cash equivalents		21,286,374			(603,428	)
Cash and cash equivalents at beginning of period		6,417,061			3,491,625
Cash and cash equivalents at end of period	$	27,703,435		$	2,888,197

Supplemental cash flow information:
Cash proceeds from interest income	$	1,398		$	22,920

Supplemental disclosure of non-cash financing activity:
Fair value of warrants issued in connection with the public offering	$	1,040,700		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. BUSINESS AND FUNDING

Description of Business

As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, and discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Our vaccine programs include the development of a vaccine against breast cancer, specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease, and a vaccine against ovarian cancer.

Our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”) relating to Wistar’s CAR-T technology. We have initially focused on the development of a treatment for ovarian cancer, but we may also pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common stock of Certainty.

Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing its CAR-T technology for treating ovarian cancer. We submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) in March 2021. In April 2021, the FDA informed us that they needed additional information before allowing us to proceed with the clinical trial. In May 2021, the FDA provided us with the details of their information request, and we are currently working with Moffitt to address the FDA’s request. We anticipate submitting our response to the FDA in June 2021, after which the FDA will have approximately 30 days to respond. Assuming the FDA finds our response acceptable, we anticipate beginning the human clinical trials in the fourth quarter of 2021.

In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”), to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we utilized advanced computational methods, machine learning, and molecular modeling techniques to perform in silico screening of over 1.2 billion compounds in chemical libraries (including publicly available compounds and OntoChem’s proprietary libraries) to evaluate if any of these compounds could disrupt one of two key enzymes of SARS-CoV-2, the virus that causes the disease COVID-19.

The screening process resulted in the identification of multiple compounds that could potentially disrupt critical enzymes of the virus. Several of these compounds were synthesized and tested in in vitro biological assays. Upon completion of these biological assays, we identified two of the most promising compounds and tested them in animal models. In these animal studies, the two compounds were compared to Remdesivir, which is the only anti-viral drug approved by the FDA for COVID-19. The data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and monitoring of weight and general animal behavior demonstrated comparable efficacy of both compounds as well as Remdesivir. Based on this promising data in the animal study, we are proceeding to the next stage of drug development and have selected one of the compounds around which we have now begun performing combinatorial synthetic medicinal chemistry to evaluate whether we can increase potency and optimize pharmacokinetics. We anticipate completing this process by early fourth quarter of 2021.

In May 2021, after completion of the aforementioned animal studies, OntoChem assigned its rights and obligations related to this collaboration to MolGenie GmbH (“MolGenie”), a company spun-out from OntoChem focused on drug discovery and development.

We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. We are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC. A specific protein, alpha-lactalbumin, has been identified that is only expressed during lactation in a healthy woman’s mammary tissue. This protein disappears when the woman is no longer lactating, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In December 2020, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1a clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1a clinical trial, and we anticipate being prepared to treat the first enrolled patient in July 2021.

In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor II protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines after menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic, to advance this vaccine technology toward human clinical testing.

In May 2021, Cleveland Clinic was granted an award for our ovarian cancer vaccine technology by the National Cancer Institute’s (“NCI”) PREVENT program. The NCI is a part of the National Institutes of Health. The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. The scientific and financial resources of the PREVENT program will be used for our ovarian cancer vaccine technology to perform virtually all pre-clinical research and development, manufacturing and IND-enabling studies. This work will be performed at NCI facilities, by NCI scientific staff and with NCI financial resources.

Over the next several quarters, we expect the development of our breast and ovarian cancer vaccines, our COVID-19 therapeutic program and Certainty’s CAR-T technology to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities regarding the Cchek™ liquid biopsy platform (operations for which were suspended in July 2020), as well as in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations, nor do we expect these activities to require material financial resources or attention of senior management.

Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current therapy or vaccine programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials.

Funding and Management’s Plans

Based on currently available information as of June 10, 2021, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the six months ended April 30, 2021, we raised approximately $20,292,000, net of expenses, through a public offering in which we sold an aggregate of 4,285,715 shares of common stock and approximately $10,834,000, net of expenses, through our at-the-market equity program in which we sold an aggregate of 2,806,410 shares of common stock. Under our at-the-market equity program which is currently effective and may remain available for us to use in the future, as of April 30, 2021, we may sell an additional approximately $29.6 million of common stock. We may seek to obtain working capital during our fiscal year 2021 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt will result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2020. The accompanying October 31, 2020 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of April 30, 2021, and results of operations and cash flows for the interim periods represented. The results of operations for the six months ended April 30, 2021 are not necessarily indicative of the results to be expected for the entire year.

Noncontrolling Interest

Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the six months ended April 30, 2021:

Balance, October 31, 2020	$	(496,983	)
Net loss attributable to noncontrolling interest		(62,124	)
Balance, April 30, 2021	$	(559,107	)

Revenue Recognition

Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive.

We follow the accounting guidance of Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. In accordance with ASC 606 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such judgments and estimates may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time.

Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.

Cost of Revenues

Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations.

Research and Development Expenses

Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, preventative cancer vaccines and anti-viral drug candidates for COVID-19, are expensed in the accompanying condensed consolidated financial statements in the period incurred.

2. PUBLIC OFFERING

On March 25, 2021, the Company completed a public offering in which we sold an aggregate of 4,285,715 shares of its common stock, which represented 15.8% of the Company’s outstanding shares at the time of the offering, at a public offering price of $5.25 per share. The Company realized net proceeds of approximately $20,292,000 from the public offering, after deducting underwriting discounts and deal expenses. In connection with the public offering, the Company issued to certain designees of the underwriter, as compensation, warrants expiring on March 22, 2026, to purchase 300,000 shares of common stock at $6.5625 per share.

3. STOCK BASED COMPENSATION

The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants.

Stock Option Compensation Expense

The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years. We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately $881,000 and $1,055,000 during the three months ended April 30, 2021 and 2020, respectively, and approximately $1,756,000 and $2,019,000 during the six months ended April 30, 2021 and 2020, respectively.

For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On May 8, 2018, we issued market condition options to purchase 1,500,000 shares of common stock, to our Chairman, President and Chief Executive Officer, vesting at target trading prices of $5.00 to $8.00 per share before May 31, 2021, with implied service periods of three to seven months. In October 2018, the first tranche of 500,000 shares of market condition options became exercisable upon achieving an average closing price above $5.00 per share for twenty consecutive trading days. The second and third tranches did not vest as of May 31, 2021. We did not record any market condition stock-based compensation expense during the six months ended April 30, 2021 and 2020.

The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $132,000 and $55,000 during the three months ended April 30, 2021 and 2020, respectively, and approximately $186,000 and $112,000 during the six months ended April 30, 2021 and 2020, respectively.

Stock Option Plans

During the six months ended April 30, 2021, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. Further, we had an additional stock option plan: the Anixa Biosciences, Inc. 2003 Share Incentive Plan (the “2003 Share Plan”), under which all outstanding options expired during the six months ended April 30, 2020.

Stock Option Activity

During the three months ended April 30, 2021 and 2020, we granted options to purchase 250,000 shares and -0- shares of common stock, respectively, and during the six months ended April 30, 2021 and 2020, we granted options to purchase 1,380,000 shares and 800,000 shares of common stock, respectively, to employees and consultants, with exercise prices ranging from $2.83 to $5.30 per share, pursuant to the 2018 Share Plan. During the three months ended April 30, 2021 and 2020, stock options to purchase 77,571 shares, net of 7,937 shares withheld on a cashless exercise, and 25,000 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $189,000 and $75,000, respectively. During the six months ended April 30, 2021 and 2020, stock options to purchase 107,451 shares, net of 7,937 shares withheld on a cashless exercise, and 43,900 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $294,000 and $104,000, respectively.

2003 Share Plan

The 2003 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future awards on April 21, 2013.

Information regarding the 2003 Plan for the six months ended April 30, 2020 is as follows:

	Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Options outstanding at October 31, 2019		400		$	17.00
Forfeited/Expired		(400	)	$	17.00
Options outstanding and exercisable at April 30, 2020		-		$	-0-	$	-0-

2010 Share Plan

The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020.

Information regarding the 2010 Share Plan for the six months ended April 30, 2021 is as follows:

	Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Options outstanding at October 31, 2020		1, 1,907,534		$	2.82
Exercised		(37,500	)	$	2.40
Forfeited/Expired		(10,400	)	$	4.57
Options outstanding at April 30, 2021		1 1,859,634		$	2.82	$	3,899,138
Options exercisable at April 30, 2021		1, 1,820,884		$	2.82	$	3,809,375

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2021:

	Options Outstanding					Options Exercisable
Range of Exercise Prices		Number Outstanding	Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable	Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$ 0.67 - $ 2.30		527,500	5.06	$	1.54		513,750	5.03	$	1.56
$ 2.58 - $ 3.13		818,000	2.90	$	2.80		818,000	3.27	$	2.80
$ 3.46 - $ 5.30		514,134	7.00	$	4.16		489,134	6.99	$	4.20

Information regarding the 2010 Share Plan for the six months ended April 30, 2020 is as follows:

	Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Options outstanding at October 31, 2019		1,998,668		$	2.80
Exercised		(43,900	)	$	2.36
Forfeited/Expired		(5,534	)	$	2.58
Options outstanding at April 30, 2020		1,949,234		$	2.81	$	291,195
Options exercisable at April 30, 2020		1,740,484		$	2.85	$	213,820

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2020:

	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price	Number Exercisable	Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$ 0.67 - $2.30	561,500	6.03	$	1.56	480,250	5.84	$	1.66
$ 2.58 - $ 3.13	853,200	3.28	$	2.79	853,200	3.72	$	2.79
$ 3.46 - $ 5.75	534,534	7.69	$	4.16	407,034	7.54	$	4.38

2018 Share Plan

The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of April 30, 2021, the 2018 Share Plan had 1,757,937 shares available for future grants.

Information regarding the 2018 Share Plan for the six months ended April 30, 2021 is as follows:

	Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Options outstanding at October 31, 2020		4,346,661		$	3.69
Granted		1,380,000		$	3.28
Exercised		(33,888	)	$	3.81
Forfeited/Expired		(392,781	)	$	3.70
Options outstanding at April 30, 2021		5,299,992		$	3.58	$	7,000,292
Options exercisable at April 30, 2021		2,626,391		$	3.66	$	3,215,984

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2021:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$	2.09 - $3.70		3,975,000		7.87	$	3.38		1,901,945		7.37	$	3.55
$	3.84 - $5.30		1,324,992		7.19	$	4.16		724,446		7.43	$	3.96

Information regarding the 2018 Share Plan for the six months ended April 30, 2020 is as follows:

	Shares		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Options outstanding at October 31, 2019		3,935,500	$	3.74
Granted		800,000	$	3.85
Options outstanding at April 30, 2020		4,735,000	$	3.76	$	-0-
Options exercisable at April 30, 2020		2,107,779	$	3.75	$	-0-

The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2020:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$	3.70		3,100,000		8.03	$	3.70		1,566,666		8.03	$	3.70
$	3.84 - $4.61		1,635,000		8.92	$	3.88		541,113		8.37	$	3.75

Non-Plan Options

In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors (the “Non-Plan Options”).

Information regarding Non-Plan Options for the six months ended April; 30, 2021 is as follows:

	Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Options outstanding at October 31, 2020		1,698,000		$	2.58
Exercised		(44,000	)	$	2.58
Options outstanding and exercisable at April 30, 2021		1,654,000		$	2.58	$	3,812,470

The following table summarizes information about Non-Plan Options outstanding and exercisable as of April 30, 2021:

Range of Exercise Prices				Number Outstanding and Exercisable				Weighted Average Remaining Contractual Life (in years)				Weighted Average Exercise Price
$	2.58				1,654,000				1.31			$	2.58

Information regarding Non-Plan Options for the six months ended April 30, 2020 is as follows:

	Shares		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Options outstanding at October 31, 2019		1,698,000	$	2.58
Options outstanding and exercisable at April 30, 2020		1,698,000	$	2.58	$	-0-

The following table summarizes information about Non-Plan Options outstanding and exercisable as of April 30, 2020:

Range of
Exercise Prices

Number
Outstanding

and

Exercisable

Weighted Average
Remaining
Contractual Life

(in years)

Weighted
Average
Exercise Price

2.58

1,698,000

2.25

2.58

On June 1, 2021, stock options to purchase 2,990,000 shares were granted under the 2018 Share Plan. Each of our non-employee directors was awarded options for 30,000 shares that vest over one year. Our Lead Independent Director, our Chairman, President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer were awarded options for 200,000 shares, 500,000 shares and 100,000 shares, respectively, that vest over three years. Further, our Chairman, President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer were awarded options for 2,000,000 shares and 100,000 shares, respectively, that vest in four equal installments upon the Company’s share price achieving targets ranging from $5.00 to $8.00 per share.

Stock Awards

On May 8, 2018, a restricted stock award of 1,500,000 shares of common stock was granted under the 2018 Share Plan to our Chairman, President and Chief Executive Officer. The restricted stock award was to vest in its entirety upon achievement of a target trading price of $11.00 per share of the Company’s common stock before May 31, 2021. The restricted stock award did not vest as of May 31, 2021. For restricted stock awards vesting upon achievement of a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). We did not record any compensation expense related to the restricted stock award during the six months ended April 30, 2021 and 2020.

Employee Stock Purchase Plan

The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the “ESPP”) which permits eligible employees to purchase shares at not less than 85% of the market value of the Company’s common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The plan was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the six months ended April 30, 2021 and 2020, employees purchased 1,634 and 9,618 shares, respectively, with aggregate proceeds of approximately $3,000 and $15,000, respectively.

Warrants

On October 30, 2020 we issued a warrant, expiring on October 30, 2025, to purchase 60,000 shares of common stock at $2.06 per share, vesting over five months, to a consultant for investor relations services. We recorded consulting expense of approximately $38,000 and $96,000, respectively, during the three and six months ended April 30, 2021, based on the fair value of the warrant on the date of grant recognized on a straight-line basis over the vesting period. We did not record any consulting expense related to warrants during the three and six months ended April 30, 2020.

As discussed in Note 2, in connection with the March 25, 2021 public offering we issued to certain designees of the underwriter, as compensation, warrants to purchase 300,000 shares of common stock at $6.5625 per share, expiring on March 22, 2026. No warrants were issued during the six-month period ended April 30, 2020.

As of April 30, 2021, we also had warrants outstanding to purchase 500,000 shares of common stock at $5.03 per share, issued during fiscal year 2017 and expiring on November 30, 2021.

4. FAIR VALUE MEASUREMENTS

US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date.

Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities.

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2021:

	Level 1		Level 2		Level 3		Total
Money market funds:
Cash and cash equivalents	$	27,038,700	$	-	$	-	$	27,038,700
Certificates of deposit:
Cash and cash equivalents		500,000		-		-		500,000
Short-term investments		-		2,000,000		-		2,000,000
Treasury bills and bonds:
Short-term investments		-		8,399,300		-		8,399,300

Total financial assets	$	27,538,700	$	10,399,300	$	-	$	37,938,000

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020:

	Level 1		Level 2		Level 3		Total
Money market funds:
Cash and cash equivalents	$	3,902,292	$	-	$	-	$	3,902,292
Certificates of deposit:
Cash and cash equivalents		2,250,000		-		-		2,250,000
Short-term investments		-		2,640,000		-		2,640,000

Total financial assets	$	6,152,292	$	2,640,000	$	-	$	8,792,292

Our non-financial assets that are measured on a non-recurring basis include our other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.

5. ACCRUED EXPENSES

Accrued expenses consist of the following as of:

	April 30,		October 31,
	2021		2020
Payroll and related expenses	$	310,641	$	415,331
Accrued royalty and contingent legal fees		577,190		449,691
Accrued collaborative research and license expense		61,853		30,000
Accrued other		29,210		6,003
	$	978,894	$	901,025

6. NET LOSS PER SHARE OF COMMON STOCK

Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the six months ended April 30, 2021 and 2020, were stock options to purchase 8,813,626 and 8,382,234 shares, respectively, and warrants to purchase 860,000 and 500,000 shares, respectively.

7. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02 (“ASU 2016-02”) Accounting Standards Codification Topic 842, Leases (“ASC 842”), which supersedes Topic 840, Leases, and which requires lessees to recognize most leases on the balance sheet. The new lease standard does not substantially change lessor accounting. For public companies, the standard was effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption was permitted. Lessees and lessors were required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance. In July 2018, FASB issued ASU 2018-11, Leases, which provides an additional transition option for an entity to apply the provisions of ASC 842 by recognizing a cumulative effect adjustment at the effective date of adoption without adjusting the prior comparative periods presented. The requirements of this standard include a significant increase in required disclosures. The Company adopted ASU 2016-02 on November 1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 9 regarding the accounting and disclosures related to our office lease.

8. INCOME TAXES

We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets.

We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have no unrecognized income tax benefits as of April 30, 2021 and October 31, 2020 and we account for interest and penalties related to income tax matters, if any, in general and administrative expenses.

9. LEASES

We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices) from an unrelated party pursuant to an operating lease that expires September 30, 2021. Our base rent is approximately $5,000 per month and the lease provides for annual increases of approximately 3% and an escalation clause for increases in certain operating costs. Rent expense was approximately $16,000 and $16,000, respectively, for the three months ended April 30, 2021 and 2020, and approximately $32,000 and $32,000, respectively, for the six months ended April 30, 2021 and 2020.

On November 1, 2019, the Company adopted ASC 842, which increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (“ROU”) assets and related operating lease liabilities on the balance sheet. The Company adopted the new guidance using the modified retrospective approach on November 1, 2019.

For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 5-month lease term as of April 30, 2021 for the Company’s lease includes the noncancelable period of the lease. The lease does not contain a Company option to extend the lease or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment.

Balance sheet information related to the Company’s lease is presented below:

	Balance Sheet Location	April 30, 2021		October 31, 2020
Operating Lease:
Right-of-use asset	Operating lease right-of-use asset	$	25,574	$	54,340
Right-of-use liability, current	Operating lease liability		25,964		55,198

As of April 30, 2021, the annual minimum lease payments of our operating lease liabilities were as follows:

	Operating Leases
2021 future minimum payments, undiscounted	$	26,880
Less: Imputed interest		(916	)
Present value of future minimum lease payments	$	25,964

10. COMMITMENTS AND CONTINGENCIES

Litigation Matters

We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition.

Impact of Coronavirus Pandemic

On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business, and which the Company’s partners operate and conduct their business. We are currently following the recommendations of local health authorities to minimize exposure risk for our team members and visitors. However, while the outlook is improving, and there has been a loosening of restrictions in many of the areas in which we and our partners operate and conduct our business, the scale and scope of this pandemic is unknown, and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business, continuity plans to reduce the potential impact of COVID-19, there is no guarantee that our continuity plans will be successful.

We have experienced certain disruptions to our business such as temporary closure of our offices and similar disruptions have occurred for our partners. Specifically, the outbreak has caused temporary shutdowns of the laboratories and other service providers that we rely on to develop our programs, and those laboratories and service providers that have been operating or that have begun operating recently have been doing so with more limited capacity due to social distancing requirements. As a result, our progress has been slowed and there is no assurance that we will be able to meet our previously announced timelines regarding the advancement of our programs.

The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition and prospects.

11. SEGMENT INFORMATION

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) Patent Licensing activities. The following represents selected financial information for our segments for the three and six months ended April 30, 2021 and 2020 and as of April 30, 2021 and October 31, 2020:

	For the Three Months Ended April 30,						For the Six Months Ended April 30,
	2021			2020			2021			2020
Net Income/(Loss):
CAR-T Therapeutics	$	(1,445,758	)	$	(495,030	)	$	(2,406,494	)	$	(1,125,363	)
Cancer Vaccines		(662,367	)		(170,271	)		(1,568,703	)		(365,867	)
Anti-Viral Therapeutics		(309,755	)		(309,504	)		(790,561	)		(309,504	)
Cancer Diagnostics		(13,409	)		(1,679,027	)		(22,371	)		(3,469,673	)
Patent Licensing		(5,600	)		(4,158	)		118,863			(4,158	))
Total	$	(2,436,889)		$	(2,657,990	)	$	(4,669,266	)	$	(5,274,565	)

Total operating costs and expenses	$	2,437,282		$	2,670,137		$	5,182,913		$	5,300,006
Less non-cash share-based compensation		(1,051,272	)		(1,110,086	))		(2,037,371	)		(2,131,420	)
Operating costs and expenses excluding non-cash share-based compensation	$	1,386,010		$	1,560,051		$	3,145,542		$	3,168,586
Operating costs and expenses excluding non-cash share based compensation:
CAR-T Therapeutics	$	934,714		$	223,822		$	1,492,394		$	570,163
Cancer Vaccines		298,537			67,059			836,525			165,329
Anti-Viral Therapeutics		138,175			221,018			408,431			221,018
Cancer Diagnostics		10,291			1,044,889			16,723			2,208,813
Patent Licensing		4,293			3,263			391,469			3,263
Total	$	1,386,010		$	1,560,051			3,145,542		$	3,168,586

	April 30, 2021		October 31, 2020
Total assets:
CAR-T Therapeutics	$	25,906,018	$	2,988,124
Cancer Vaccines		8,265,734		946,923
Anti-Viral Therapeutics		3,825,876		2,464,361
Cancer Diagnostics		332,450		2,869,529
Patent Licensing		167,444		184,027
Total	$	38,497,522	$	9,452,964

Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Information included in this Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020 and the condensed consolidated financial statements included in this Report. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Report.

GENERAL

We discuss the description of our business in the Notes to our Condensed Consolidated Financial Statements.

RESULTS OF OPERATIONS

Three months ended April 30, 2021 compared with three months ended April 30, 2020

Revenue

We had no revenue during the three-month periods ended April 30, 2021 and 2020.

Inventor Royalties, Contingent Legal Fees, Litigation and Licensing Expenses

We had no inventor royalties, contingent legal fees, litigation and licensing expenses during the three-month periods ended April 30, 2021 and 2020.

Research and Development Expenses

Research and development expenses incurred in the three months ended April 30, 2021 associated with each of our development programs consisted of approximately $548,000 for CAR-T therapeutics, approximately $336,000 for cancer vaccines, approximately $118,000 for anti-viral therapeutics and $-0- for cancer diagnostic.

Research and development expenses are related to the development of our cancer therapeutics, vaccine and diagnostics programs and our anti-viral drug program, and decreased by approximately $207,000 to approximately $1,022,000 in the three months ended April 30, 2021, from approximately $1,229,000 in the three months ended April 30, 2020. The decrease in research and development expenses was primarily due to a decrease in outside research and development expense related to our cancer diagnostics program of approximately $305,000 and decreases in employee compensation and related costs, other than stock option compensation expense, of approximately $124,000 and employee stock option compensation expense of approximately $89,000, all due to the suspension of development of our cancer diagnostics program. In addition, no license payments related to our collaborative agreement with OntoChem concerning discovery and development of anti-viral drugs for COVID-19 were required in the current period compared to approximately $111,000 in the prior year period. These decreases in expenses were offset by an increase in research and development expenses related to our other development programs of approximately $331,000 and an increase in consultant stock option and warrant expense of approximately $78,000.

General and Administrative Expenses

General and administrative expenses decreased by approximately $26,000 to approximately $1,415,000 in the three months ended April 30, 2021, from approximately $1,441,000 in the three months ended April 30, 2020. The decrease in general and administrative expenses was primarily due to a decrease in employee compensation and related costs, other than stock option expense, of approximately $100,000, a decrease in consultant expense of approximately $78,000, a decrease in director compensation of approximately $38,000, offset by an increase in patent expense of approximately $110,000, an increase in shareholder relations expense of approximately $54,000 and an increase in corporate insurance expense of approximately $25,000.

Interest Income

Interest income decreased by approximately $12,000 to less than $1,000 in the three months ended April 30, 2021, from approximately $12,000 in the comparable prior year period as a result of a decrease in interest rates.

Net Loss Attributable to Noncontrolling Interest

The net loss attributable to noncontrolling interest, representing Wistar’s 5% ownership interest in Certainty’s net loss, was approximately $38,000 and $18,000, respectively, in the three months ended April 30, 2021 and 2020.

Six months ended April 30, 2021 compared with six months ended April 30, 2020

Revenue

For the six months ended April 30, 2021, we recorded revenue of approximately $513,000 from one license agreement. The license agreement provided for a one-time, non-recurring, lump sum payment in exchange for a non-exclusive retroactive and future license, and covenant not to sue. Pursuant to the terms of the agreement, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Accordingly, the performance obligations from this license agreement were satisfied and 100% of the revenue was recognized upon execution of the license agreement. As discussed in Note 1 to our condensed consolidated financial statements, as part of our legacy operations, the Company remains engaged in limited patent licensing activities which we do not expect to be a significant part of our ongoing operations or revenue.

We had no revenue during the six-month period ended April 30, 2020.

Inventor Royalties, Contingent Legal Fees, Litigation and Licensing Expenses

Inventor royalties, contingent legal fees, litigation and licensing expenses increased to approximately $385,000 in the six months ended April 30, 2021 from $-0- in the six months ended April 30, 2020. The increase was primarily due to the increase in related revenues. Inventor royalties and contingent legal fees are expensed in the period that the related revenues are recognized. Litigation and licensing expenses related to patent assertion, other than contingent legal fees, are expensed in the period incurred.

Research and Development Expenses

Research and development expenses incurred in the six months ended April 30, 2021 associated with each of our development programs consisted of approximately $910,000 for CAR-T therapeutics, approximately $630,000 for cancer vaccines, approximately $288,000 for anti-viral therapeutics and approximately $2,000 for cancer diagnostic.

Research and development expenses are related to the development of our cancer therapeutics, vaccine and diagnostics programs and our anti-viral drug program, and decreased by approximately $869,000 to approximately $1,850,000 in the six months ended April 30, 2021, from approximately $2,719,000 in the six months ended April 30, 2020. The decrease in research and development expenses was primarily due to a decrease in outside research and development expense related to our cancer diagnostics program of approximately $816,000 and decreases in employee compensation and related costs, other than stock option compensation expense, of approximately $394,000 and employee stock option compensation expense of approximately $194,000, all due to the suspension of development of our cancer diagnostics program. These expense reductions were offset by an increase in research and development expenses related to our other development programs of approximately $428,000 and an increase in consultant expense of approximately $51,000.

General and Administrative Expenses

General and administrative expenses increased by approximately $367,000 to approximately $2,948,000 in the six months ended April 30, 2021, from approximately $2,581,000 in the six months ended April 30, 2020. The increase in general and administrative expenses was primarily due to non-recurring income in the prior year period resulting from the discharge in January 2020 of a disputed liability of approximately $337,000 upon the expiration of the vendor’s statutory right to pursue collection of the disputed liability, an increase in patent expense of approximately $186,000, an increase in corporate insurance expense of approximately $47,000, an increase in directors compensation of approximately $43,000, offset by a decrease in employee compensation and related costs, other than stock option compensation expense, of approximately $248,000.

Interest Income

Interest income decreased by approximately $24,000 to approximately $1,000 in the six months ended April 30, 2021, from approximately $25,000 in the comparable prior year period as a result of a decrease in interest rates.

Net Loss Attributable to Noncontrolling Interest

The net loss attributable to noncontrolling interest, representing Wistar’s 5% ownership interest in Certainty’s net loss, was approximately $62,000 and $42,000, respectively, in the six months ended April 30, 2021 and 2020.

LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of liquidity are cash, cash equivalents and short-term investments.

During the six months ended April 30, 2021, cash used in operating activities was approximately $2,412,000. Cash used in investing activities was approximately $7,724,000, resulting from the purchase of short-term investments of approximately $10,399,000, which was offset by the proceeds on maturities of short-term investments of approximately $2,640,000 and the proceeds from the sale of equipment of approximately $35,000. Cash provided by financing activities was approximately $31,422,000, resulting from net proceeds of approximately $20,292,000 from a public offering of 4,285,715 shares of common stock, the sale of 2,806,410 shares of common stock in an at-the-market equity offering of approximately $10,834,000, proceeds from exercise of stock options of approximately $294,000 and proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $3,000. As a result, our cash, cash equivalents, and short-term investments at April 30, 2021 increased approximately $29,046,000 to approximately $38,103,000 from approximately $9,057,000 at the end of fiscal year 2020.

CRITICAL ACCOUNTING POLICIES

The Company’s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America. In preparing these financial statements, we make assumptions, judgments and estimates that can have a significant impact on amounts reported in our condensed consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.

We believe that, of the significant accounting policies discussed in Note 2 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020, the following accounting policies require our most difficult, subjective or complex judgments:

Revenue Recognition; and

Stock-Based Compensation

Revenue Recognition

Stock-Based Compensation

The compensation cost for service-based stock options granted to employees, directors and consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years. For employee options vesting if the trading price of the Company’s common stock achieves certain price targets we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period.

For restricted stock awards vesting upon achievement of a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest).

The Black-Scholes pricing model and the Monte Carlo Simulation we use to estimate fair value requires valuation assumptions of expected term, expected volatility, risk-free interest rates and expected dividend yield. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. For employees we use the simplified method, which is a weighted average of the vesting term and contractual term, to determine expected term. The simplified method was adopted since we do not believe that historical experience is representative of future performance because of the impact of the changes in our operations and the change in terms from historical options. For consultants we use the contract term for expected term. Under the Black-Scholes pricing model, we estimated the expected volatility of our shares of common stock based upon the historical volatility of our share price over a period of time equal to the expected term of the grants. We estimated the risk-free interest rate based on the implied yield available on the applicable grant date of a U.S. Treasury note with a term equal to the expected term of the underlying grants. We made the dividend yield assumption based on our history of not paying dividends and our expectation not to pay dividends in the future.

We will reconsider use of the Black-Scholes pricing model and the Monte Carlo Simulation if additional information becomes available in the future that indicates another model would be more appropriate. If factors change and we employ different assumptions in future periods, the compensation expense that we record may differ significantly from what we have recorded in the current period.

EFFECT OF RECENTLY ISSUED PRONOUNCEMENTS

We do not believe that any of the recently issued accounting pronouncements will have a material effect on the Company’s consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As of April 30, 2021, we had investments in short-term, fixed rate and highly liquid instruments that have historically been reinvested when they mature throughout the year. Although our existing instruments are not considered at risk with respect to changes in interest rates or markets for these instruments, our rate of return on these securities could be affected at the time of reinvestment, if any.

Item 4. Controls and Procedures.

We carried out an evaluation, under the supervision and with the participation of our management including our President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13(a)-15(b) of the Exchange Act. Based upon that evaluation, our President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of the end of the period covered by this Report.

There was no change in our internal control over financial reporting during the second quarter of fiscal year 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None.

Item 3. Defaults Upon Senior Securities. None.

Item 4. Mine Safety Disclosures. Not Applicable.

Item 5. Other Information. None.

Item 6. Exhibits.

10.1	Assignment Agreement dated May 1, 2021, between the Company, OntoChem GmbH and MolGenie GmbH.

10.2	Amendment 2 to the Collaboration Agreement between the Company and MolGenie GmbH. (Certain information has been redacted in the marked portions of the exhibit.)

31.1	Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated June 10, 2021.

31.2	Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated June 10, 2021.

32.1	Statement of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated June 10,2021.

32.2	Statement of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated June 10, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ANIXA BIOSCIENCES, INC.

	By:	/s/ Dr. Amit Kumar
		Dr. Amit Kumar
		Chairman, President and
		Chief Executive Officer
June 10, 2021		(Principal Executive Officer)

	By:	/s/ Michael J. Catelani
		Michael J. Catelani
		Chief Operating Officer and
		Chief Financial Officer
		(Principal Financial and
June 10, 2021		Accounting Officer)

Exhibit 10.1

Assignment Agreement

This Assignment Agreement (“ASSIGNMENT”) is entered into as of April 30, 2021, (“Effective Date”) by and between OntoChem GmbH, a German limited liability company registered at the courts of Stendal whose address is Blücherstrasse 24, 06120 Halle (Saale), Germany (“ASSIGNOR”), MolGenie GmbH, a German limited liability company registered at the Courts of Stuttgart (“ASSIGNEE”), whose address is Felix-Dahn-Str. 4, 70597 Stuttgart, Germany, and Anixa Biosciences, Inc., a Delaware corporation, located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, U.S.A. (“ANIXA”) (each a “Party” and collectively the “Parties”); and with reference to the following facts:

WHEREAS, ASSIGNOR has performed certain drug discovery research and consultancy services in the discovery and development of novel drug candidates for the treatment of COVID-19 on behalf of ANIXA under the umbrella of a Collaboration Agreement, signed on April 14^th, 2020, as amended (“Agreement”). Capitalized terms used but not otherwise defined herein will have the respective meanings given in the Agreement.

WHEREAS, ASSIGNEE has been formed to perform drug discovery research and consultancy services;

WHEREAS, ASSIGNOR would like to assign to ASSIGNEE the Agreement, as well as assign and transfer all rights and materials that are needed to continue the performance of the Agreement, such as chemical building blocks, hit compounds, biology screening materials such as substrates and proteins screening data, and also all related data and other subject matter that were generated under the Agreement (for example, screening data and synthesis and testing procedures);

WHEREAS, any such assignment requires the consent of ANIXA, and ANIXA desires to consent to the assignment contemplated herein; and

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

1. Assignment. ASSIGNOR hereby irrevocably transfers, conveys and assigns to ASSIGNEE: (a) all of ASSIGNOR’s interests, rights, duties and obligations under the Agreement; and (b) all of ASSIGNOR’s interest, rights and title to all (i) Hit Compounds identified under the Agreement as of at any time prior to the Effective Date, and all Variants of such Hit Compounds (as well as all physical samples of such Hit Compounds and Variants), and (ii) all Deliverables (completed and in process), Inventions, data and records generated under the Agreement as of at any time prior to the Effective Date (the foregoing assets under this clause (ii), collectively, the “Collaboration Assets”).

2. Assumption of the Assignment. ASSIGNEE hereby assumes from ASSIGNOR all of ASSIGNOR’s interests, rights, duties and obligations under the Agreement and agrees to comply with all terms and conditions of the Agreement as if ASSIGNEE were the original party to the Agreement. Promptly following the Effective Date, ASSIGNOR will destroy all materials containing ANIXA’s Confidential Information then in ASSIGNOR’s possession, and, notwithstanding the destruction of such materials or anything to the contrary in this ASSIGNMENT, ASSIGNOR will continue to be subject to the terms of Section 5 of the Agreement with respect to ANIXA’s Confidential Information.

3. No other liabilities. Except as expressly and specifically provided in this ASSIGNMENT, ASSIGNEE shall not assume any other liability or obligation of ASSIGNOR of any kind whatsoever, fixed or contingent, disclosed or undisclosed.

4. Representations and Warranties of ASSIGNOR to ASSIGNEE. No warranties or representations of any nature whatsoever, either express or implied, are made with respect to the Agreement or with respect to the title, condition, design, fitness or marketability of the assets associated with the Agreement, and there is expressly disclaimed (i) any implied warranty or merchantability, (ii) any implied warranty of fitness for a particular purpose, and (iii) any implied warranty of conformity to models or samples of materials with respect to the Agreement, it being the express intention of ASSIGNOR and ASSIGNEE that the Agreement and the Collaboration Assets shall be conveyed and transferred to ASSIGNEE in their present condition and state of repair, “as is” and “where is,” with all faults, if any.

5. Representations and Warranties of ASSIGNEE. ASSIGNEE represents and warrants to ANIXA that as of the Effective Date of this ASSIGNMENT:

a. It is a duly organized corporate entity in good standing and is fully authorized to enter into and perform under this ASSIGNMENT and the Agreement;

b. Neither ASSIGNEE nor any of its Affiliates has been found in breach of any laws or regulations governing the production of medicinal products in the United States or any other jurisdiction within the world;

c. Neither ASSIGNEE nor any of its Affiliates has been debarred by the FDA or other regulatory authority outside the United States from working for or providing services to any pharmaceutical or biotechnology company under Section 306 of the Federal Food Drug & Cosmetic Drug Act or comparable laws of any other jurisdiction, and, to ASSIGNEE’s knowledge, no investigations, claims or proceedings with respect to debarment are pending or threatened against ASSIGNEE or any of its Affiliates.

d. ASSIGNEE has never approved or commenced any proceeding, or made any election contemplating, the winding up or cessation of ASSIGNEE’s business or affairs or the assignment of ASSIGNEE’s material assets for the benefit of creditors. To ASSIGNEE’s knowledge, no such proceeding is contemplated, pending or threatened.

e. (i) to ASSIGNEE’s knowledge, ASSIGNEE’s performance of its activities under the Research Plan does not infringe or constitute misappropriation of the intellectual property rights of any third party; (ii) no licenses, permissions or releases from any third party are necessary for ASSIGNEE’s performance of its activities under the Research Plan; (iii) ASSIGNEE has obtained rights to use any third-party compound libraries and software referenced in the Research Plan under terms and conditions consistent with the Agreement to the extent necessary to perform the Research Plan from and after the Effective Date; and (iv) ASSIGNEE’s performance of its activities under the Research Plan will not result in any third party acquiring any right, title or interest in or to any Anixa Invention or Deliverable.

6. Release of ASSIGNOR. ANIXA hereby releases and discharges ASSIGNOR, its officers and employees, administrators, agents, partners, or other legal representatives from any further obligations and claims arising from the Agreement after the date of this ASSIGNMENT, excluding, for clarity, any obligations and claims based upon a breach of the Agreement that occurred prior to the date of this ASSIGNMENT.

7. Entire Agreement. This ASSIGNMENT and the documents and instruments and other agreements among the Parties hereto referenced herein constitute the entire agreement among the Parties with respect to the subject matter hereof and supersede all prior written and oral agreements and understandings, and all contemporaneous oral agreements and understandings, among the Parties with respect to the subject matter hereof.

8. Severability. In the event that any provision of this ASSIGNMENT or the application thereof becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this ASSIGNMENT will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the Parties hereto. The Parties further agree to replace such void or unenforceable provision of this ASSIGNMENT with a valid and enforceable provision that will achieve, to the greatest extent possible, the economic, business and other purposes of such void or unenforceable provision.

9. No Assignment. This ASSIGNMENT is not assignable by any Party absent prior written consent of the other Parties.

10. Waiver. No failure on the part of any person to exercise any power, right, privilege or remedy under this ASSIGNMENT, and no delay on the part of any person in exercising any power, right, privilege or remedy under this ASSIGNMENT, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

11. Governing Law. This ASSIGNMENT shall be governed by, and enforced and construed in accordance with, the laws of Germany without regard to any conflict of laws principle that would result in the application of the laws of any other jurisdiction, provided that the Agreement, and the rights and obligations of the Parties thereunder, will be governed by the laws of the State of Delaware without regard to the conflict of laws provisions of any jurisdiction.

12. Counterparts. This ASSIGNMENT may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Any signature page delivered by facsimile or electronic image transmission shall be binding to the same extent as an original signature page. Any Party that delivers a signature page by facsimile or electronic image transmission shall deliver an original counterpart to any other Party that requests such original counterpart.

[Remainder Intentionally Left Blank]

IN WITNESS WHEREOF, the Parties have executed this ASSIGNMENT on the date first above written.

	OntoChem GmbH (ASSIGNOR)

	By:	/s/Felix Berthelmann
	Name:	Dr. Felix Berthelmann
	Title:	Managing Director

	By:	/s/Lutz Weber
	Name:	Dr. Lutz Weber
	Title:	Managing Director

	MolGenie GmbH (ASSIGNEE)

	By:	/s/Lutz Weber
	Name:	Dr. Lutz Weber
	Title:	Managing Director

	ANIXA BIOSCIENCES, INC. (ANIXA)

	By:	/s/Amit Kumar
	Name:	Amit Kumar, PhD
	Title:	CEO

Redactions with respect to certain portions hereof denoted with “***”

Exhibit 10.2

AMENDMENT NO. 2 TO COLLABORATION AGREEMENT

This AMENDMENT NO. 2 TO COLLABORATION AGREEMENT (the “Amendment”) is made as of May 1, 2021 (the “Amendment Effective Date”), by and between Anixa Biosciences, Inc., a Delaware corporation (“Anixa”), and MolGenie GmbH, a German limited liability company (“MolGenie”). Anixa and MolGenie are referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, Anixa and OntoChem GmbH (“OntoChem”) entered into a Collaboration Agreement dated as of April 14, 2020, as amended (the “Agreement”);

WHEREAS, all of OntoChem’s interests, rights, duties and obligations under the Agreement have been assigned to MolGenie pursuant to that certain Assignment Agreement between Anixa, MolGenie, and OntoChem dated as of May 1, 2021;

WHEREAS, the Parties desire to expand the scope of the Research Plan attached as Exhibit A to the original Agreement pursuant to Section 2.1 of the Agreement; and

WHEREAS, Anixa agrees to provide additional funds to MolGenie to complete such additional activities under the expanded Research Plan.

NOW, THEREFORE, in consideration of the foregoing recitals, and the mutual promises herein made and exchanged, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree to the following:

1. Terms. Capitalized terms in this Amendment shall have the same meaning as those in the Agreement, unless specifically defined in this Amendment.

2. Amendments.

2.1 References to OntoChem in the Agreement are hereby replaced with MolGenie, as applicable.

2.2 The scope of the Research Plan is hereby amended to include the additional activities set forth in Schedule 1 attached hereto. Schedule 1 is hereby deemed attached to and incorporated into the Research Plan under the Agreement. MolGenie hereby agrees to perform its obligations under the Research Plan, including Schedule 1, in accordance with this Amendment and the Agreement.

2.3 Section 3.1 of the Agreement is hereby amended to include the following subsection (f):

3.1(f) pay MolGenie the amounts set forth in Schedule 1 of the Research Plan within thirty (30) days after delivery of an invoice therefor (including reasonable supporting documentation), in accordance with the budget and payment schedule set forth therein.

2.4 The address and information of OntoChem for notices set forth in Section 9.3 of the Agreement is hereby deleted and replaced with the following:

MolGenie GmbH

Felix-Dahn-Str. 4, 70597 Stuttgart

Germany

Attention: Dr. Lutz Weber

Email: lutz.weber@molgenie.com

-1-

Redactions with respect to certain portions hereof denoted with “***”

2. Interpretation. Except as expressly modified herein, the Agreement shall remain in full force and effect in accordance with its terms. To the extent there are any inconsistencies or ambiguities between this Amendment and the Agreement, the terms of this Amendment shall supersede the Agreement.

3. Governing Law. This Amendment and the rights and obligations of the Parties hereunder will be governed by the laws of the State of Delaware without regard to the conflict of laws provisions of any jurisdiction. The Parties agree that the 1980 United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Amendment.

4. Counterparts. The Parties may execute this Amendment in multiple counterparts, all of which together will constitute one instrument. Signatures to this Amendment delivered by facsimile or other electronic transmission (e.g., portable document format (PDF)) will be deemed to be binding as original signatures.

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

ANIXA BIOSCIENCES, INC.		MOLGENIE GMBH

By:	/s/Amit Kumar	By:	/s/Lutz Weber
	Amit Kumar, Ph.D.	Name:	Dr. Lutz Weber
	President and CEO	Title:	CEO

-2-

Redactions with respect to certain portions hereof denoted with “***”

SCHEDULE 1 TO EXHIBIT A: RESEARCH PLAN

M^proInhibitors Lead Optimization Phase

***

-3-

Exhibit 31.1

CERTIFICATION

I, Dr. Amit Kumar, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Anixa Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	By:	/s/ Dr. Amit Kumar
		Dr. Amit Kumar
		Chairman, President and
		Chief Executive Officer
June 10, 2021		(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION

I, Michael J. Catelani, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Anixa Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	By:	/s/ Michael J. Catelani
		Michael J. Catelani
		Chief Operating Officer and
		Chief Financial Officer
		(Principal Financial and
June 10, 2021		Accounting Officer)

Exhibit 32.1

Statement of Chief Executive Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Dr. Amit Kumar, the Chairman, President and Chief Executive Officer of Anixa Biosciences, Inc., hereby certifies that:

The Company’s Form 10-Q Quarterly Report for the period ended April 30, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Dr. Amit Kumar
		Dr. Amit Kumar
		Chairman, President and
		Chief Executive Officer
June 10, 2021		(Principal Executive Officer)

Exhibit 32.2

Statement of Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Michael J. Catelani, the Chief Operating Officer and Chief Financial Officer of Anixa Biosciences, Inc., hereby certifies that:

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Michael J. Catelani
		Michael J. Catelani
		Chief Operating Officer and
		Chief Financial Officer
		(Principal Financial and
June 10, 2021		Accounting Officer)